Tralokinumab for Eczema: 4 ECZTRA 3 Checks

The American Academy of Dermatology¹ strongly recommends tralokinumab among systemic treatments for adults with atopic dermatitis. Its current guideline page includes the 2025 focused update. That recommendation does not make this injection interchangeable with another biologic or remove the need to discuss topical treatment.¹

What was added?

ECZTRA 3 randomized 380 adults with moderate-to-severe atopic dermatitis to tralokinumab or placebo. Both arms used mometasone 0.1% cream as needed. Tralokinumab began at 600 mg, then 300 mg every two weeks.²

Bring the names, strengths and body sites of your topical prescriptions to the consultation. A useful question is: “If I start injections, which cream stays on my hands, which stays on my face, and when do I reduce each?”

US Adbry labeling covers patients aged 12 and older whose moderate-to-severe disease is inadequately controlled with prescription topical therapy, or when that therapy is inadvisable. It permits use with or without topical corticosteroids.³

Which improvement counted?

At week 16, clear/almost-clear skin occurred in 98/252 versus 33/126: 38.9% versus 26.2%. Adjusted difference: 12.4 percentage points, 95% CI 2.9–21.9.²

EASI 75, at least 75% improvement in the eczema area/severity score, occurred in 141/252 versus 45/126: 56.0% versus 35.7%. It does not mean clear skin.²

Before starting, tell the dermatologist which affected area or activity you most want to change. Photograph the same area under similar lighting and record nights interrupted by itching. Ask how those observations will sit alongside the clinician’s skin assessment at review.

Who was counted?

One undosed patient per arm was excluded. Rescue treatment or missing week-16 responses counted as nonresponse. Both primary tests passed hierarchical testing. LEO Pharma sponsored the trial; four authors were employees.²

Keep a record of extra treatments used between visits, including their dates. If you need another prescription during a flare, tell the eczema team rather than leaving it out of the history. Ask how much additional treatment would prompt an earlier review of the plan.

What do later results mean?

Week-32 maintenance described selected week-16 responders, without a comparable placebo group. It does not predict maintenance for all starters.²

The US label allows consideration of 300 mg every four weeks only for adults below 100 kg who achieve clear/almost-clear skin after 16 weeks. Do not extend the interval yourself.³

Report new or worsening eye symptoms. The label warns about conjunctivitis and keratitis, and serious hypersensitivity including anaphylaxis. Stop Adbry and seek immediate medical attention for a serious allergic reaction. Complete age-appropriate vaccines before starting and avoid live vaccines during treatment. Pre-existing worm infections need treatment first. Discuss pregnancy or breastfeeding because human data are limited.³

Ask who will answer an eye-symptom call, how quickly the clinic can arrange assessment and what your topical plan should be while waiting for the next review.

Skin, Head to Toe includes “What to Say at the Appointment.” It asks readers to bring their product and medicine history and describe what the skin problem costs them day to day. Use that preparation to describe interrupted sleep, painful handwashing or clothing you avoid, then bring those particular difficulties into the treatment discussion.